⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15841346 | 0.90 | MEN1 (0.35) | — | |
| SCHEMBL19170260 | 0.88 | — | — | |
| SCHEMBL16013455 | 0.86 | EPHX1 (0.30) | — | |
| SCHEMBL17522636 | 0.83 | — | — | |
| SCHEMBL17284109 | 0.81 | — | — | |
| SCHEMBL17525150 | 0.80 | LMNA (0.36) | — | |
| SCHEMBL23571648 | 0.77 | SIGMAR1 (0.33) | — | |
| SCHEMBL29900403 | 0.77 | — | — | |
| SCHEMBL15889149 | 0.77 | — | — | |
| SCHEMBL459140 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946460-B1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260007768-A1 | CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12364771-B2 | Conjugation linkers | PROLYNX LLC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-119970617-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240181397-A1 | HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE | PROLYNX LLC (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4308649-A2 | HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE | Prolynx LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117098811-A | High flux microemulsified membrane | 普罗林科斯有限责任公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022198052-A2 | HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE | PROLYNX LLC (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220280654-A1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220265873-A1 | STEAM STERILIZATION OF HYDROGELS CROSSLINKED BY BETA-ELIMINATIVE LINKERS | PROLYNX LLC (US) | 2022-08-25 | — | — | US | disclosed |
| EP-2670767-B1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017161174-A1 | EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS | PROLYNX LLC (US) | 2017-09-21 | — | — | WO | disclosed |
| US-9085514-B2 | Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof | EMBL (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085514-B2 | Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof | EMBL (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085514-B2 | Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof | EMBL (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20140073764-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073764-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073764-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2014-03-13 | — | — | US | disclosed |
| EP-2670767-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012104422-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2012-08-09 | — | — | WO | disclosed |